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In Taiwan, liver diseases rank as a leading cause of mortalities. 
Portal hypertension is a major complication of chromc liver disease. In 
patients with portal hypertension, variceal bleeding is one of the main 
causes of death. The exact mechanism of bleeding from esophageal or 
gastric varices has not yet been elucidated. Although the hemodynamic 
changes of portal hypertension are well characterized, the cause and 
development of the hyperdynamics in portal hypertension are still to be 
clarified. 
The aims of this study are two folds: (1) to investigate the vascular 
hyporesponsiveness and possible changes of phosphoinositide signal 
transduction pathway in the aorta and portal veins of portal hypertensive 
rats (2) to study the hemodynamic effects of synephrine (a pure 
compound from Fructus Aurantii) in portal hypertensive rats. 
Partial portal vein ligation (PVL) \vas perfonned in Sprague-Dawley 
rats to mduce portal hypertension. Fourteen days after surgery, the tissue 
weights of aorta from PVL rats were similar as compared to sham­
operated (Sham) animals, but the tissue weights of portal vein from PVL 
rats were higher as compared to sham-operated (Sham) animals. In vitro 
vascular reactivity study was conducted in the organ baths using aorta 
with phenylephrine, acetylcholine and phorbol 12,13-dibutyrate (a protein 
kinase C activator). In [3H]-inositol phosphates response, basal contents 
IX 

of [3H]-inositol phosphates in aorta and portal vein were similar between 
the two groups. Phenylephrine induced concentration-dependent increase 
of [3H]inositol phosphates formation in the aorta from both groups. The 
responses were significantly smaller in the PVL group than in the Sham 
group. Both phenylephrine and angiotensin II stimulated [3HJinositol 
phosphate fonnation in portal veins, but the response were attenuated in 
the PVL group. In contrast, the [3H] inositol phosphate responses by 
nomeceptor-mediated stimulation (GTPyS, NaFIAlCl3, and phospholipase 
C) were similar between the two groups. Our results suggested that in 
aorta from PVL rats the vascular hyporesponsiveness was reflected in the 
contractile response due to the agonist, and in the receptor-coupled 
inositol phosphates formation. The contractile responses due to activation 
of protein kinase C were not impaired. Endothelium-dependent relaxing 
response to acetylcholine was also unchanged. In portal vein fonn PVL 
rats the receptor-mediated [3H]-inositol phosphates fonnation was 
attenuated, and the site of impairment possibly was at the receptor-G­
protein coupling level. 
Synephrine is a pure compound from Fructus Aurantii. \Ve found 
that synephrine increased mean arterial pressure, cardiac illdex, and total 
peripheral resistance in the anesthetized rats in the two groups. Increases 
in mean arterial pressure and total peripheral resistance could alleviate the 
hyperdynamic state of PVL rats, whereas increase in cardiac index might 
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d i a c y1 g 1 yc e r 0 1 ( D A G) ,1+ WI ~{,- tUl At R~ H e age r t y and 
Ollerenshaw, 1990) 0 dJ }tl:.)l FJJ - it , a~ ~GJ At 1*J -~Jl ,~, 1Jt 
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.::::.-. " G-protein 
G-protein 
~ fiX. El9 ~ 14- Jt 1;-- ft (heterotrimers) 0 * 'f Ell] a subunits 
G -pro t e in -!J}~!ii Ell] 1:.t- it ' -*.i. -*- %- ~ IrQ 1@ ~;5J:( (f0 u r 
fam1lies) Gs " Gil Go " Gq :fp (Ohanian and Heagerty,G I2 
1995) 0 4.;£: lift ( -9P ,1;-1t ) fiJ( ~ at ' J.±. G-protein sl] a 
subunit .l * - GDP , JEll.:fp (3 r -subunits Jt 1;-- 4 ­
GDP Eil] 1;-- j; Ft1f:i ' dJ GTP ~1\ a -subunit sl]GDP , 1R G-
pro t e in ,1;- 1t ;1;- 1 t 1~ it fiX. a :fp (3 r -sub un its '0"- i1JIi ' a0 
( GTP) ;fo;3 r -subunits -Pt ii! .iT T Wf Eil] ~J~ n 11: m a 
fiX.a (GDP) 
r -subunits j-t 1;-- , [§J jlj -9F if; it 71j sl] G-protein ( Neer, 
1995 ) GTPyS nonhydrolyzable GTP analog, 
G-protein ifij aluminium fluoride0 
heterotrimeric G-protein Ell] 11;-1t~IJ (Sternweis and Smrcka. 
199'J, ,j:4l 'i7T rR ;h ,;'$ A J$ -,i-J. G p"ote~n 0"""'" ) -J '" ITJ .?0-- (./1-;'" / \ ••. :.1"'1'- P,J - I. J J. 1 
~ " Phosphatidylinositol phospholipase C (PLC ) 

,11 1t 1:t Ell] G -protein 'itT if; it. pho sp ho li p as e C 0 

o 0 it:>it llN;fo G -pro t e i n -I inke d r e c e p tor ft /p"­
PLC-ps 11: m 0 PLC-'YI ;fo growth factor ;tIJ ~%t receptor 
9 

tyrosin kinase 7]<.. M- phosphoinositides 1f n~ , rtn. PLC-ys 
{~ ~ ,f;IJ Jllj *- 3;0 (Ohanian and Heagert)·, 1995) 0 't P LC .;{; 
1t, 1!t Jj1j or 7]<.. M- PIP 2 ;t 1- IP 3 :fo D A G f.8 1@ " sec 0 n d 
messenger" (Berridge, 1993) 0 
1m " Inositol 1,4,5-trisphosphate (IP 3 ) 
tb Xfr1t, f1~ PLC 7]<..M- PIP2 ;t 1- IP 3 :fo DAG IP 3 4~lji0 
A #.m ~e? pg, or ~ ~m J~e? 0J W#.~ J:. f1~ I P 3 1:: tt ,*i % ' 1~ r9 WN~l 
J:.~~~+~ h~'~~.+~A~~W~ 4+~~' 
it ~ A - ~ ~f; iilJ ~ + 51i Jt J:. * f1~ irL I~' (Hamet et a1., 
1995) IP 3 rt A -t B it; 1t, , ~lJ itt iilJ ~ + ~ it 'it ~0 
calcium-calmodulin complex ,{;1t, myosin light chain kinase 
rtn. If 1- - ~ ~f; f1~ u,t AAl (S 0 m1y 0 and S0 m1yo, 19 9 4 ) 1P3 
~ - 1@ 'fR: it lL ~ii \Ii' f10 #.m ~e? r9 iiJ ~ + ;!:<g no' I P 3 e 1R 'fR: ;fIt 1\ 
) J.: ..crJ. • 1
I \. ';;j,. . 
inositol 1,4 bisphosphate ( IP2) '-ft-.3E:f ij~ rt A ~m Jl~ 0J :ftl) ~li 
+ f19 ¥~' ik c rfi1 I P 2 -t- 1t 1\ ~M A in 0 sit 0 1 1 -ph 0 s p hat e :fo 
inositol 4-phosphate ' JlHt1t1fj A inositol 0 2. IP] 
1.i f10 pfll: ~~ 1t, , 1l} A in 0 sit 0 I 1, 3 , 4 , 5 - t e t r a k i s p h 0 s p hat e 
( I P 4) Jl:t: §. k 0\.. +e :f 11 rt A #.m ~e? 0J f10 iilJ f4iI + *¥ it, Ht 
IP 4 *pfll:m~1t,;t1- inositol 1,3,4-trisphosphate' rtn.Jl:t*:i~qbJ 
:tt I P 3 1:: 1ft ,yJt:flJ fJ I j, Ji}/i 1.t e A {~ ili -i±- -t 31 ~1. >}!fiJ ;tIl ;~i 8t0 
I P 4 or tti§] ~(a] IP3 ltD AA- # #.m Jl~ 0] iilJ ~iI + f10 {~* ' 18 I P 4 f1(J J.f'. 
fIJ E.' El h;J173;fJ*i~ (Ohanian and Heagerty, 1995) 
10 

" 1,2-diacylglycerol (DAG) 

DAG -or;'1; 1t protein kinase C (PKC) 

i:t HE # fJi £r~ ~t 'it J! ~ itt ~ 1t filamin-actin-desmin 
( Rasmussen et al., 1987) '~:1]":¥:[ 1,'1 ~ ,'f; 1t protein 
kinase C ~~):tg 5~J11r. ~t~ EJ Jf'ft Ca2, 6~iiji~lr1- (Itoh et 
aL, 1988) ,Jt Jl ,'f; 1t it 6~ protein kinase C J,i :1] * ~m 
Bt 0J iil) i!#i -f- 6~ ;JL. T ~E. ~;} ~ J11r. if ~t i:1§ (J iang an d Ivl 0 rga n, 
1987; Itoh and Lederis, 1987) 0 F~ Jl:t. ' tb fi;;{ 1): ffl t~ no 
Ca2+ :;fn DAG or WI] ~& N a+ -H+ :;fn N -Ca2+ 6~ X 
$~ k J! PKC rrij ;& itt 1ii~ 1t 6~ *-' jtJl PKC ~ or 
~ 1t Jtg 5~ L-type a~ Ca 2+ i! ,'f; 1[1. ( Hathaway et al., 
1 9 9 1) D i a c y 1 g 1 y c e r 0 1 6~ 1~). 4b.i ph 0 r b 0 1 est e r ~E. 1I:..0 ~ 
PKC, Jl:t.#IJi4b.i 1f *1i ~ it enzyme ~'- ,10 llJJ~{\. rl}J DAG 
11:.. PKC 6~:r}] ~s (Heagertv and 01lerenshaw. 1990 ; 
D A G ~ 1! ~ ~J 100 lJ:} ;f~ i,t 0- fi3If : - 100 1! i?& d i a c y 1g1Yc e r 0 1 
kinase 1R DAG 10 phosphatidic acid ' - 100 di - ;to 
m0 n0 g 1 y c e rideli pas e 6~ de a c y 1 at ion a~ 11: rn ~ it ' 121:: A0 
~m ~E ~ J:. 6~ arachidonoyl-specific DAG kinase or ~ {a 
DAG 6~1~JM:1f ~~ (Ohanian and Ileagerty, 1995) 0 
J-!.. nn p"" "",I..G-protein ~ phospholipase C ;jiIJ ~*i rrij J:.. [J!u Pf: ~~ 
riD Jl F~ ~Ik a~ ~Jt *- ~%~ ~{'- ~h mR 'R ~(~ i; 
11 

~x j-' A ~Jt (Cummings et al., 1986; Kaumann and 
Groszmann, 1989; Wong et al., 1995) '~.1rt:.;f\iF'J 1f­
*- %r 1~} :it 1f r, ~Jk ~* 0 
,iff bt 1t.1"R ~ El~ - :J:~ 1# 1f*- ' or -tJt r, ,~Jk ~ & ~ ~ mnt EJ:. 1t 
ht i! tx. El~ it y}, T -9f~ tf j@ Elry 11;- #Jt '* 1f fJt Eli) ;}:; filS !Jo 1!"- M0 
o J,u f '$ Jr~ •-x \\.£2;.. 1_ 
"!iBft 10[ -ko ? .Li 1El 8 ,qi ~k ~ ~t. *- *-~ Jf ~ft ~'e. ~l 
Jli M~ , Jtc.ft irk ~ 0 "( 1: -t) fm ~ ,~tt Ek ~ Eli [tJ " ~Wt. 
Jl2 :it ~1~ " 41" ~:it" :it, flp Eft ffii .z;fR l El 




7j(. )\/!JY... ' 
,~ , ;}eAli J5zAm Z 5G itt ik ( tf
*i~, 1991) c 
, Ft 
(,~ iE , 199] J'1 c 
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.::... " ;t;:; Jtl (Fructus Aurantii) ('f -* ~ tQ 'f *~~, 198 5 ~ 
'* ~, 1991) 
Poncirus trifolia (L) raf " m'-i.~'if:.Citrus aurantiul11 
L. " -ff- 00 C. wilson Unaka ~ J1\ J1\~~ C. au ran t ium L. 
va r. amara Eng /. .;iff ilt ;& ~~ *- -t 0 
(~~)~ *~~"~~~.0'ftQ ~~~~~~~~ 
o 
, p-£5- , 
6;:";:Bk , ~ \1~ it. , T .ffi 1£. , ~i JP:. , -f­
r-~ ~9 0o I..., 
-~ "tJ \1~3 ,{x(m~!-m ) l*1 J:Jft , m, i0/5 .;<'>:, < *- ~IJ O.5~2 r,f,:; / is<.. A 
( f~ iJ1&. ) Ft ?~ $t ;l:i h\ ' Fi5" i#l " Fi5" ~i 0 
_H­
( EX. 10- ] if ;t;:; ;t1 J~ 1'- {£f- 1f ~th ;fp * it " synephrine" }.;­
methyl tYramine Cirrus.' ~ 
aurantium var. amara *- *- 6~ *- Jt.. 'f i1JT~'if:. 
Jt..1t (Neohesperidin) ; *­ ;& 
14 

aurantium *-t'tf ,1t-?:it :~c 36,6~82,1 Jtl100 
Jto
( * J}:) '1. tt I\.; -1l'n.1f 69 11 JfJ : ~ ,{rtf 1E ~~ tb ig '*1: 11 -7+ -1l'n. fI9 
11 JfJ ' r?i7.i.."* * .:rfu. ~ 69 A St ~ ~ ~11 k synephrin e 
It N- methyl tyramine ( r-* il}, 1980, r,'R i:f 
1981) 'r?i7 synephrine Z 11 JfJ k :R 4i- 1;" a ~ 
1* ' N -methyl tyramine 511] k lift:i@ :;5t f*J ~ ~;fo/ 
~§}.4h}f catecholamine, Fa' ~i-~1t a ;;f11 /3 ~ 1* r?i7 
1f.:jlfi 11 JfJ 0 Synephrine E.. ~11 k a - ~~ L &t. 1~ 
jlflJ ' \if y:;' ~ fi .:rfu. ~t ~ ( r-* ilf ¥, 1 9 8 1, Mi~;h ~ 
¥, 1 9 8 3) ,11 :ill \if 11 ~-t 69 ~t; #. Jt ;ffij A :tW fJl1 !f.. 
#Jt, It.i -1l'n./f: ' r?i7 -11- ~9 ffi.. J.@. rh :;5~ ,\.; fJlL ~t ~.f5 tJ fJl1 ~~ 
( cardiotonic) 'I\.; *~ tb }£ :tW fJl1 It Jill. 1f ~t ~±. *­
FIT 0 





2f- > ~t.1b 11 JfJ (AA iE ,1991) 0 
3 , Wff 1f 69 fj ~ :ig ;f11 ig ,it + ~ .%. 69 ~)i 1* 11% 
rh Mi iE ii\ ( 1 9 94) 69 *Jf 3t ' 1Jt m~;\ tf:R t~ ,~iK 5£ ~t 




~~ 1t t8 ;&1;; - Synephrin e ;HJ;tr F! F~ ~& fi1:: 89 11 If] , lL £ JP... 
8dose-dependent B9 J)L *- ' 1 ~ -i.t?tZ -tt jlj ;tr n~ i{- I~ ~ffj ill & J~ 
~m~¥~~h~~~*m*-'~~~~~ ~ 





1. 	 ~;:}; ~~1:.JJf~Li!~ Gould polygraph (RS 3400, Valley Vew. 
Ohio, U.S.A.) 
') 	 ~~t force transducer FT03 (Grass Instruments, QUIncy, 
Mass. U.S.A. ) 
3. 	-t*~~~ strain-gauge transducer (P23XL, Viggo-Spectramed, 
Oxnard, CA, U. S.A. ) 
4. 	+ft(j'1tjf~~*: forceps, needle holder, hemostatic forceps, 
surgical scissors, spring scissors, vascular clamp. 
5. 	 Polyethylene catheter-50 (ID:0.58mm, OD:0.97mm. Clav 
Adams, Parsippany_ N.J .. U.S.A.) 
6. 	 Polyethylene catheter-l0 (ID:0.28mm, OD:0.61mm, Clay 
Adams, Parsippany, N.J., U.S.A. ) 
7. 	Polyethylene catheter-240 (ID: 1.67mm, OD:2.42mm,Clay 
Adams, Parsippany, N.J., U.S.A. 
8. 	 3-0~,*i/t 
<1,:; '.hI bl.;f:L ::>;:. i!> r+1 <1- l,bt biz.. M d IBM ,.., 2 9 7 ,.., 3 (' M ". T h/1.­9 . ~-Jd~ 7 I . -'I'T -r frcr 'T /TJ ~~ 1jj,x.~JG 0 e .L. -' . e IJlee 11 0 _ 
Japan) 
10. :k AP 210 S (OHAUS, Switzerland 
11. 'flL~jji~t HAKKE D8 (Berlin, Germany) 
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12. ~j(;~ Sorvall RI 6000 B (Du Pont) 
13. pH meter RE 375 Ix (IDI, U. K. ) 
14. ,{t U fAJ ~ it It ~ ~-counter ( LS 6500, Beckmann 
Instruments, Fullerton ) 




1. 	 yJ T ~jlfll AA: §J Jt ~ 1t, *..I. *- ~~ i( 1f~± ( E! ;f.) (i'R. ~ - 1& ' 
1& ) 
Sodium chloride (NaCl) 
Potassium chloride (KCl ) 
Calcium chloride (CaC1 2 ) 
Sodium bicarbonate (NaHC0 3 ) 
Glucose (C 6 H 12 0 6 ) 
Sodium dihydrogen phosphate (NaH 2P0 4 .2H 2 0 ) 
Magnesium sulfate (MgS0 4 . 7H2 0 ) 
Sodium fluoride (NaF) 
Aluminum chloride (AIC1 3 ) 
Ammonium formate (NH 4 COOH) 
Formic acid ( HCOOH ) 
2. 	 yJ Ttt(jlfIJJ!~ §J Sigma ( St, Li ous, MO, U. S.A. ) 
Acetylcholine chloride (ACh) 
L-Phenylephrine hydrochloride (PEP) 
DL-Synephrine 
Ascorbic acid 










3. ~~*Jt,tj: m*R1K~,tt ( -t; 
Sodium pentobarbital 
Cefmetazon 




9. 	 yJ T ~~~jf mJ1. Baker (U.S.A.) 
Chloroform (CHCI3 ) 
Methanol (CH30H) 
Ether (C2Hs ) 20 
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10. Hydrochloride (HCl) JlJt mMerck (Germany) 
12. Phorbol ester (Phorbol 1 13-dibutyrate) ~~ m RBI (Naticko MA, 
U.S.A. ) 
13. Myo-[3H]inositol 5l~ mAmersham (International pic, U.K. ) 
14. 	 Scintillants (Ready safe) Jl~ 2:J Beckman lntruments ( Fullerton, 
CA, U.S.A.) 
15. 	 YA *~5l~ 2:J BIOMOL (Plymouth Meeting, PA, U.S.A. ) 
GTPyS [guanosine-5' -0- (3-thiotriphosphate) , tetralithium salt} 
Phospholipase C phosphatidylinositol-specific. from Bacilills 
cereus) 
16. 	Dowex anion-exchange resin ( 100-200 mesh, formate fonn) 




iii Iri Spragu e -D awl e y ( S. D. ) *- E1 it ' p'~ [r 1% SJJ *- ~f; jJfJ 
I ") 3 cC-~ ,I -r?\ ~ , /Y-...230 -250 Jl:- 5t ' 
I 

































- " r, ~*- ~ ~"ffJ 4h t~ i( (Portal hypertensive animal model) 
,'Mt ~ 7} ~* rn Chojkier lZ Grozmann ( 1981 ) H7 
~~ ~JR ,~t 1f: (partial portal vein llgation, PVL) 7i ';fFj {ti 
no YA 11f ~~, #i A :r-}) it /\.. A YA 0 Jfx. j[ y 23 0 -2 5 0 Yw 
Sprague-Dawley (S.D.) XEl g\. ' rn l..M~d~~ , 0 
,#~~ o~~, m~~M~ ± 
HR #11 ~ J1IJ ~ -f 1fl. -+ #:f (Sham)' 1:n .y .~~~ ~ 
, -!It YA Sodium 
pentobarbital (50 mg/kg) tb 11lt!~~ ~t r~i'§~1i * .;£- k\. ~Il 
J~ tf FJJ ' m I~~ ~t ~JR :till ~M r~ ~JR & ' ~ 1J ~~ 
( transducer) , m§7 5;7 fit J.2 tG i;Jt ( G 0 u 1 d , R S 3 4 0 0 I &G 




r, ~~ ~e. 7t 'lfJdt ' *~~ *- EJ ~ z lit ~ iR liJ ~ FJJ ' ljx. tB 
~ ttJ ~ II r, ~t~ , .:;i t1] ~~,. lift 1f 95 % 02/5 % C02 )~:fu #c as 
Kre b s -Hen s e 1 e it (K-H) 5t tf (1'-1f C a C 12 2. 1 m M, K C 1 5 
mM, NaCl 115 mM, MgS0 4 1.2 mM, NaH 2 P0 4 1.2 mM. 
NaHC0 3 25 mM, Glucose 11 mM) M.g.,] {ili T'~-i­0 
..mz. if ~ if] as nf3 JVi #.-\' I J,,-:.; frJ 1~ 0J ;tJt o.in. tJ) A Ji~ io9 4 
mm 'ii!-ft ~ 0 
1. P V L II Sham rf;;J fA ::t t" f4fi H ~ .i:. if; fllR.in. ,it. 1J Jt ,~ 
~~ ~~*4mm'*~rf;;J~~~.~~'-~OO~~ 
( transducer) , tb ~ :r}] ~L1. ~e.}ffi: (Gould, RS 3400) ~e.}ffi: 
~t~ 1J ~ 11::. 0 Tissue chamber A Z K solution - lift T 
:\9 ci~ it (wate r bath ) 37 
~ .i:. ttJ ~JR z.in. ::err '* w.1J Jt 2 jt, , :0-+~m- ~l, 
ifl 
io0 - I J' at 1t jp;J 
A KCl 60 m1vl 'W(,% RJIi' -fIt ik -i-1t *'* ~t 0 it):\:..y ,~~ 
1i jlJ 2 IX. K C 1 z ~t ~ R JIi {EI 1;,L , -*- if;' ~t ~~ II -fIt Jft.A1. 
~~*ii!B ~~#~ 0 ~Jt*~'~T~.in. ~ ~~ 




rtij 5J ~ ery Ja. ~t ~ k ~ ;f M 0 nil *- 7f -j( YA J: nil 
T ,PEP (10-9_10-5M) 0 
( 2 ) Acetyl choline (ACh) .z. if 1tt R j,@, 
~ PEP ( ] 0 -9M - 1 0 -5M) 5J ~ ~t M3 ' 4t R fi.& **- {it t~ 
TACh nil it i (] 0- 9-1 0-5M) ,~~ 0J }~3Rt~ If1. ary it 11: 
m ' WJ flL F~j k ~ ~ '* 0 
(3) Phorbol 12,13-dibutyrate (PDBu) .z.~ti~Rfi.& 
411: ACh R J@:{it ' jJt -!- ACh ' .in. tt ~ It - Ij, 3'f ' * F~ 
2 0 ~:it ~ .t~ -;k. K -H sol uti 0 n 0 - + 3'f {it i@- - ~IJ {/J 
PDBu (Phorbol 12,13-dibutyrate, 3 x 10- 6 M) '51 ~k --t 
nr 211 ~t i@ , R)fl ~1'li J:.. -1+ ' R J@: f;~ 3 0 )} :it 
fiJJ 4h ~t -at Fsj R!fl.. tif7 f7t 0 
2. Total inositol phosphates .z.jfllJ Y 
Total inositol phosphates .z.~Jl~ tI?dt Huang A a0 
~} (H u an get a!., 19 89; H uan get a1.. 19 9 5 c) 714 Jjx.. tB0 
{Jry *~ .i.. JJJR {t1 (1 -~t M( , ~t A -JG 95 % O 2 / 5% CO 2 ~ ttl 60 
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:5tA1'- 2.5 jJ. Ci [3H]-myoinosito1 i:. 0.5 Illl KRB ,{~ tf 
J:g,;J- 3 I J \ at ( 37°C ' 95% 0 7.1 5 % CO 2 ) , 11 [3 H ] ­
ill Y 0 in0sit 01 i:. loa din g ; 3 .j \ at 1& 7t rn K -H 5.t I~ 5t i;t,' :5t 
A *" Li C 1 10mM i:. K -H;~ rf J# -t 10m i n (3 7 ,9 5 %) 
0:21 5% CO 2 ) 1& ' no A ~ 4i:J 11: m 0 
( 1 ) 	 ~J.i.. ffJ Mf. : Phenylephrine 10-9~ 10- 3 MAO, 1% 
as cor b i cadi c (v e h i cl e) 11: rn 20m i n 0 
(2) 	F1~t~1R : Phenylephrine 10-6~10-4 1\1 "Angiotensin 
II ]0- 7 -10- 5 M" GTPyS 10-4 M "Phospholipase 
CO, 5 U 11 rn 20min' N a F ( 10m1\1 ) 1Ale 13 (9 0 
j.l M) 	11= rn 60 III in 0 
4£1 11 	 rn 1&};A 2 ill1 f~ JL 5't l{;t C H C13 : I'v1 e 0 H ' H C I 
( 2 0 :4 0 : 1 v 1v) '*- M- JL ffi.. fl! 'it list J11z. 1f ill t~ 4' fJ\J i nos Ito I 
ph 0 s p hat e s (IPs) lli11b M- JL ~~ ,It -R ;r: no 1.t~ fJ\J 1!*, 14 T fro R~ n~0 
M ~t -1P ~<" if fit ' lli1 ,Jt ;;jiIJ m 2 - 3°C 1ki ~.iliutt ~ -T ' YA ~ "it it. J% 
45 III i n 1~ ~ro A~ Mi lh M~t ' 13- no A C H C 13 (0, 6 3 III J) ;}o H2 0 
( 1. 26m1) 1~ i:. "n'-- A ~ Ji A T 1~ ~ Ji it. 11 ' YA 2 5 00 rpm0 
-:ko IPs ' 
lysophosphatidylcholine ( PC ) sphingomyelin 
Iysop h 0 S Phat i dy1 e t han 01 ami n e (PE) ';fo T }It n~ 5,t .[1:. ~bJ 'W J:J.[l 










inositol mono- , bis- , tris- phosphates (IPs) ,PC, PE ' 
sphingomyelin ~ , ~fol ~ p H 1~ , 1~ -if 6. 8 - 7 . 2 z fell ' run 
0.6g Dowex anion exchange reSlI1 colum Dowex 1-x8 
~ ~ 
res in' 100 -200me s h ' pH 4. 0 - 5 . 0 ) z;fit 7t m 10 ml 
un1abe 11 e d my 0 in 0 sit 01 ( 5 m M ) )t i5t col u m n ' 1>t 
[3H]-myoinositol iJt t* -iI}- m 60 mM NaCOOHI 5mM0 
Na 2 Br 4 0 7 15 ml )'f i;t : ~ VA 2 ml 1 :tvi ammonium formate 
( :;&~ O. 1 M for m i c a c i d) )t iJt ' ~t *$t, ili 
[3 H]­
myoinositol t~ m PLC 
( ph0 s p hoI ipas e C) 7]<. AA- % ~ [3 H ] - i nos ito 1 m 0 n 0 - , b j s - , 
tris- phosphates ag i 0 ~t *JiIJ ag 2 ml ili ;{t , no A 10 111 I 
sintillant' m j3 -counter ~J!~ *i5c~t,r.i )ilt 0 
,'..::j:.. 
1'0 ( in vivo) JX..~ 
, -iI}- rA K e tam in e 
'tJJ ~}~ (femoral 
(B.P.) ,artery) fA PE- 5 0 
( P . V . P.) );t It fJ M;. If: 0 rf.] ;;; 
..}.., U AI;;. K (t d )JJ iT I'll::; \ rans ucerOP 
1. Propranolol:&. Synephrine ~+ WJ tll.:;:t w\.·:t.A'F m 
~ M*~~~.~ a a 'M~~~ ~ * 
(iffiE propranolol Z I~) iX. 0.1 % H Cl (iffiE synephrine 
I~) ){f ( inf use) ,)it It )~q1fIJ (vehie1e) ~+ FJf ~ JJt ?f; ~;. 
tk .:t~ ~t 11 ~~ j}:j ~ , 1}- U; propranolol ( 0.3.1.5 
mg/kg/min) 8min ~ synephrine (0.1, 0.2, 0.4 mg/kg/minJ 
6min 0 ~ 'l. j/J 4h P. J~ {: - *4h ' 11 ~ -1~ ~j .f.:J;' tbj ­
) 
2. Car d i a c 0 u t put ~J!~ 

Cardiac output ;ttt iJit A I bill 0 s }'" ( 1992
 
~f- RJR.z P E -5 0 .tift 1f ;]T A the r m a lin die at 0 r 
( 0 1 \ . 1m~, 0 001 N C 1.//0 ~ a,., t1i: U- -k,"p;.1,[.rp::.. 1 8 ()....L () .:::. or.V~.V.-' v \J 
;~ fjJiJ 37 . 0 . O. 5°C ,~~ 15 ti ~ !it ;}~ card i a c 0 u t put 
computer' IX *- ~;J 1i~;Jl~1-1--1~ data, ~1~ data ;]TA 3 4 
iX thermal indicator l/X..JtfJ:S] 1iQ. rb cardiac output/per 100g0 
body weight oJ 1-1- cardiac index (mIl min' 1OOg) 'rb rnean 
arterial blood pressure/ cardiac index l1f 1-1- total peripheral 




1. 	Krebs-Henseleit solution 
CaC1 2 2.1 mM 
KCl 5.0 mM 
NaCI 115.0mM 
MgS04 1.2 mM 
NaH 2P04 1.2 mM 
NaHC0 3 25.0 mM 
Glucose 11.0 mM 
7t #4 J:. i! ~ yy. - Ik 7]<. ~E ~ Jfi 20 z s t 0 ck sol uti 0 n 1% 
1t i~ ,7}<. tf' 1t mat yy' 1: 2 0 Wf~ 0 
") 	 KCl: it i~ - ;j: 7JC. oE A 3 Ivl z stock solution '1R 81 
organ bath ( 10 ml) hp /"-. 200f.l1 }if m.. 60 mM 0 
3. 	 PEP : ~t i~ 0.1 % ascorbic acid ~E Jfi ]0- 2 M stock 
solution yy' 1.5 ml z eppendoff 9t '1*1ti~ _700( ;7}~ t~ 
tf,~m*~10~# *'~~#~JfiM~~ 0 




5. PDBu : ~~ * Dl\1S0 lic, A 5 x 10- 3 M ' y).. eppendoff 0­
o!it ' 1%* * -70 e ;J}c*~ t 0 
6. 	 [3 H] -ill Y0inos ito1 : Jtx. 900 J-ll - IX 7J<.- ' j),o A 1 0 0 J-ll [3 H ] ­
ill Y0 in 0 sit 0 I ;;5t A 5 c c ffi]J * if rf ».; sto c k soluti 0 n ,1% 1t­
-20
oe ;¥ *m rf 0 
s t 0 C k so] uti 0 n 1% * i/'- 1: 
8. 	 Angiotensin II: ~t7i{--;x7J<.-illiEA 10- 3 M stock solutIon 
y).. eppendoff 0-!it ' 1%#7i{- -70De ;J}c~ rf 0 
9. N a F / A Ie 13 : ;~ 7i{- - ;x 7J<- rtBG A N a F ( 1 00 111]'vi) /A Ie 13 \ 90 () 
J-l M ) s t 0 C k sol uti 0 n y).. e p pen d0 f f 51'-;}~ , 1% # 7i{- - 70 
10. GTPyS : 5~ 7i~~ - ;x 7J<.- lic, IX. 10-3 M stock solution YA 
11. Heparin: :fi} vial 1t 5000 units/ ml ' 1~ mat y).. 1:50 1.. 
J.I it- ~ 7J<.- #- ,,' 0 
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] 2. Dowex ani on exchange re sin: Jf9.. 20 g j}l1 A 20m 1 -;k 7]<. 
]3. 	Propranolol YJ-;.k7Jl(~:';&]0 mg! ml c 
14. 	Synephrine: YA 1% HCI f3G;& 20 mg!ml' 1tffl BcfYA-(~7.k 






error of mean ) -*­ '1.. ~. 
1 
_ Jt.i4- Ji] 1& ' }A Stu den t ' sx.. 





~ - ~r PVL 1t Sham jJl ~ &'\. ~ ft (in vitro) AJv 
i -tfJ ~~ a0 Jfu. if R g!, Itt 

~ " Phenylephrine (PEP) ~tf~ fo...)@;' 
!:7~ ~ c 
~f;- T PEP , ~£ ili Q' 1 *-!t..~;ftf7 j£ ft tiD ~1~ 60 JfIL ~t i~ R 
3 x 1 0 -6, 1 0 -5 M ' S h a ill ill R J.@, Jb O. 5 8 . O. 1 1, 1.4 8 0 1 1 , 
1.80=0.10,2.11 .0.10,2.08-0.10 it ,PVL ill~llJb 0.30= 
0.04,1.00-;0.12,140-0.10,1.67=0.11,1.65--':"-0.]6 
.=. " Ace t y 1 c h 0 Iin e (A Ch) z if 1!t fo... hi 
!:$. ~ 0 
-4 PEP ( 1 0 -9 - 10 -5 M) ~ 1 #- ~t ~ it jlJ ~t, ;t Mk at' J~ 
J~ ~ A C h ~ iJv i1f!1 ( 1 0 -9- 1 0 5 M) '1f ± rkJ Jt 1~ *~ 'ft 8(J if 
1!t 1Jp m ' JJ:r. if 5k R J.@, -4 P V L J!J... S h a111 if,:; jJl fit it l:- Jt 51 :t1 




iil 3 *- IF ?% l' P D B u (3 x ] 0 -6 M) '* ~t ~ - B:;Y r~j R 
Ji Ub t.* ®J 0 
?%1' PDBu (3 x 10- 6 M) , 
cr 0~ 1~ : P VL 3 3 8 = 0 .23 g : Sham 3. 5 8 0.29 ::;, 
1~i -r- ~ll ( Sham ) 
,4ft;.ElJJIJi -* (345+19 VS. 367_14 g) F'L%~..~ Sham P'J 
6.8 	 0.3 mmHg , PVL #.m. Jl1ltf fl,~ ~ILL-Jt 18.7 0.9 mmHg c 
:i '* (3.8 = 0.1 VS. 3.8 
_ 0.1 g) 0 FJ ~* Jh 1f ft a0 i.{f. Sham j,~ 1.1 0.1' PVL 
fJl JlIJ S}] ~Ji };r.1 A; 1. 7 0 . 1 1L 0 
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iW\.RSui:..t})M~' * [3H]-IPs;,iN R~Ub#t~ 0 
;.t £ l'Jl M. ~ -r P VL ;fu Sham 1f9 #Jl a~ [3H] - IP s Jt ~i 1f 

6~ (195.6_,-6.7 vs.179.6._15.7 cpm!mg tissue weight) riD
C' 
af] ;t~ 6~ ~t Sham #Jl IJ (% bas a1 ley e1s ) : 1 0 -8 M ( 1 ] 7 ~ 8 %1 
PEP ( 10- 9-10- 3 M ) -*1] ;*t T t7J :fr jlJ eH]-IPs dose-
dependent a~ J<g flo , -it 10- 8-10- 5 M at PVL ~ flo a~ ~ !:~ 
' 
vs.139 4%) '10 7 M (150_8% Ys.208"-16%) '10- 6 M 
(199-;-19% vs.271 ·22%) '10- 5 M (227=14% vs. 304_ 
30%) 0 
,., 
PVL ;fu Sham 
WI. f~ ~*- ' * [3 H] -IPs ~IJ R}Ii Ub ~t ~ 0 
;.t £hJi~k~ T PVL ;fu Sham Ri-J tJl6~ [3H]-IPs 
6~ (467...L 6 8 v s . 403 _ 28 cpm! mgtiss uewe i g h t) PEP0 
( 10-6-10- 4 Iv1) -*11 ;iWt t7J jlJ [3H]-IPs .£ dose-dependent 6(] 
~ flo ' PEP 1 0 -6 , 1 0 5, 10 -4 at 6~ [3 H ] - IPs (% bas all eve1s ) 
.&-~ PVL: 128=8%,133 __ 6%,163 18%; Sham: 133 
14 % , 1 9 8 -'-- 17 % , 4 3 9 = 82 % 10 -5 ftl 10 -4 M at ' P V L .:l:rg0 
flo 6~ 11 0'- ~t k Elf] J~ 6~ ~t Sham fJl ~ j-' 0 
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iii 6 -;J:: yJ- ~;t Jt Angiotensin II tIl ~~'t PV L ;:fO 
Sham ilL:€ ~\ r~ R~ , * [3 H ] - IPs 1!f1] i R lib t'lt ~ 0 
J.±. Angiotensin II (10- 7 -10- 5 M) tlJ i~tT u~ [3H]-IPs 
iJF £ do s e - de pen den t 60 pg 1;0' A II 1 0 -7 , 10 -6 , 10 -5 I\1 
a0 [3 H ] - IPs (% bas a1 I eveIs) ~~ P V L : 1 2 3 . 1 1 0/0, 1 4 0 = 
6%,150.5%; Sham: 167-18%,187-'-15%,196=13%. 
10 -6 ;fa 10 5 M a~ , P V L '±W I;cr 60 ~ rt E;~ a0 rt S h a I1l 
*11 * j-' 0 
*- 2 : yJ- nonreceptor-mediated ~ 4h jf:11 ;~i PVL ;:fo 
Sham ~ flL:€ fir\. r~ ~~ , * [3HJ-IPs Li ±z11 ~ rl: 0 
J.±. GTPyS ( 10-4 M) 'NaF ( 10 mM) IAIC]3 (90 
11M) ,Phospolipase C (0.5 U) tIl "T::.t jlJ [3HJ-IPs a0 
- " Propranolol It ffl fl1:€ 11 m 
Propranolol 0.3 ' 1.5 
mg/kg/min B~: (1) Cardiac mdex : 4 Sham t11.R 
:t 1f aA ~J1 at) 1$1Ji ' J.±. PV L ill ffl1~ 11rlJ .±~ 1f s}j 1Ji s ( J ) • - I 
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-t J£j 'f;j J3{~ ~ : ;,t~ ~IJ at ilL:t ~ J£j :;fj oj] ;.1-~ 89 ft 1t" l 1~ ~I1i'IJ at 
PVL iJF ~ E,~ J~ 69 Ft 1~ 0 (3) %J rJl JJ : 1~ ~IJ at R>J ill ::t if\. 4 
~~h~~~~~M ~'4~~ *R>Jtt:t~~~~~~~ 
4 * 4 'f;.1-~ IF ' R>J ill :t ~~ -f Syn eph r i n eO,] , 0, 2 , 0 4 
mg/kg/min at: (1) Cardiac index: R9 ilL:t if\.;,t ":="1®j1l"j J±] 
:;fj Ej] ;.1-~ * 0 (2) -t ;5.] tfJ flJR & : R>J ill :t if\. 4 ..:=.. 1!§J ~IJ J±] ;tJ Ej] 






1:--~ Jf ~ til )t {f :t :\. ~ 1~ r~ RJfc~t ~~ (P V L) itt ~ i- i1! 
it a0 ' ~ ffi; J.t ~~ itt ~J £ Jt~ :t ~'t r, RJR If: ~ k ;xt- ~fJ :h 6~ 'r± 11 
or it -f£[ ;f.t Jt ~:t ~ (S i ku 1eretaL, 19 8 5) 0 
* - ~p PVL 1t Sham :t tt\. ~ftA~ £t/J ~~ fJ~ k 1f 
~t~RJ!A:i 
PVL it. ~~ ~ at; ~t Sham 1t ' ilD tb ;i;1t Protein kinase C .i!: fiX. 
z~t~::fO tb ACh i!fiX.z Endothelium-dependent 6t;it7iL&'"-},:'~ 
c (2) Jt iff 'r± >It ~ (tonic contraction I : 
* it. ~Hl ~~ )11' ~iJ ~r1 -T pg ;t i'Jt i! ~ 0 {f Jl:t. ,~ 'f :t jlj * ~Hl ~~ )11' 
~iJ at ' PVL it PEP at; 1R.J.it SJJ ~iW a0 ~t Sham 1: 0 ilD 1£;if,-- ,~it 
. ft PEP 60 Ji.. 
Jlt ' P V L 173 H:, S ham 
;(£ fJo A A C h iJ I~ 60 it 7k /7.. Jlt, -t- )t :It ~ end 0 the in m ­
depen den t rei a x a t ion ilD 1t1l k 1f -t i'lli- mt if 7k (K 0 m 0 r i eta 1. , 
1988; Vanhoutte, 1989) ';if'--1flWi'fJoA ACh --jjUij 8j]k 
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'If I*J ItEJryXJl-I[1. ' h 7~~f;}JJt-R PVL ;fv Sham fJlk5t~ 

EJry 0 § ~~.i;t 7i rm 173 ~ tt ; -¥-tffiJ : ~ ta ~-R PVL ~ l¥\. ~t ACh 

~l ~ if ~k &. ~ k ~ rtf ~~ !t EJry (Karatapanis et a!., 1994; 
M i chie1sen etaI. , 199 5) , 1E!. ~ ~ A t~ tB A C h 
metb a c b 0 lin e ;,t IEJt Ai! 'i l: EJry ~ A tX. ::t ~\ -t-::l:t JJo end 0 the 11 u 111 ­
dependent if 5k &. ~ (Claria et al., 1994; Al billos et a!., 
1995) 0 
PDBu k--{~ protein kinase C EJryi1;1l:jlfil, or ;&-f-nr!'JJL 
EJry f.;£ 'Ii ~t ~ ( Abebe and MacLeod, 1990; Mori et aI., 
1990) ,1; 'it protein kinase C -R ~ I*J i k :i1t ~ 1,2­0 
diacylglycerol *- $ 1t r7D phorbol ester ( PDBu ft - -{~0 
ph 0 r b oles t e r) JIll it .!! m.. ~t ~ 1[1. EJry ~ E7 Jr it ii) ~ -T ~ ~!t ::l:t JJo 
( Somlyo and Somlyo, 1994; Walsh, 1994) -R lLt {Jry tfi0 
t~ tB ,PDBu h\ ~t i:15:fO }!J ii) -T EJry ~ ~ Jt;1; no i 
20-kD a myo sin light chain (MLC 20) EJry J;# ~ 1l: (Itoh et al., 
1993; Masuo et aI., 1994) 'r7D MLC 20 EJryJ;#~1l:5Z..k ;&-.!r 
;1t mL ~t M5 -1!§J j[ ~ EJry ~ ~%- m ~ 1r1 EJry h~ *- 1~ 4';0 : PVL ;fv Sham0 
YA P D B u ,*'Ltt JJSu tn mk YA q~ -R ~t f~ .L it ~ , IIp *- -;F P V L 
-R pro t e inkinaseC if n~ EJry ~t fffi jt 1~ it *- ~~!t 0 1'A r7D ' # if ta 
%t;t. tB YA l-indolactam ( h --{~ protein kinase C EJry i1;1t.~'; ) 





~-=-~r 	 PVL a Sham :t-~~kiftHJLiffi~LG4r!t~ 
a0R.~ 
4- J1~J i:.. in !~JR -j; Ui:J 1f Jyt Jfu. 1f j't PEP E1 liZ ~ , ~ pet 4­
organ bath *- JJ)v ili E1 Tk jJ t£ Jt inositol phosphates E1 
:M:) Jyt do s e - d e pen den t 81 Jyt ~ 0 ;f.. -r Mt 1:: jJ - ~ If'" Jt -finnJR E1 
0.jiJt 1t (H u an get a1. ~ 199 5c) '-tt 1f :tm r~ E1 Jt *- dJ Jr. # ar %p 
173- m*' tL~JR ~ & E1 Jfu. If 1t. liZ h~Ai ar liZ s:k: 4- ph 0 sphi nos it ide E1 
~ €l ~ x,' l-	 0pfl 1'->.' :r- ..1t J­
dJ :;5~ F9 A*- ~ & Jfu.1f 1t. liZ ~ I~i -'f!X :1' ~t ~*- -j; Ui:J E1.jiJt Fi:J .f\ 
1r'J ~ -tt E.. Nt ~ jlJ 4- PVL ~ it", E1 F9 nJR j't NE E0 ~t liZ h&. tV'] 
~~E0~t Sham 1t. (Huang et al., ]996) 0 [t]Jl:..f\1F1:£t - "F9 
~t JlJR" ~* A J* it ' J* it FJ B*- ~ & ~ If'" t inositol phosphates 
R & aar~fZs:k:iliJfu.lf~fZ~li~~~o 
agoni st) PEP in A II [3HJ-inositol phosphates E~J 4­
PVL 1f;?]J it 80 Fit- 1t. ; ffiJ i1t ~ qF {: ~ ~ 4h (non-receptor­
mediated) GTPyS , NaF/Ale13 ' in Phospholipase CAli] ittB-j 
~ fJL ~ W'" E0 liZ h! k #Ji 1~ E1 0 
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± ~~ :$ -=- itt t~' "s e con d me sse 11 g e r " 11!­
~.i. -*- k d7 : Agonist fo-t % ilJ Receptor JjiIJ ~*i G-protein rrij 1R. 
1l Phospholipase C 5i-1t: ' tfij5i-1t: ~~ Phospholipase C 1r1!Z1l 
PIP 2 7}(.JW jf ± :i! ~ F*J -j,{; ~t fi ;&. # it ~t ~ f,f,:J 1lB Jt Jt ,ri. ~~ Second 
messenger : Inositol 1,4,5-triphosphate ( IP 3 ) ;fa 1,2 
diacylglycerol (DAG) (Somlyo and Somlyo,1994; Walsh, 
1994) 0 
*- jf J~@: 4' ' .a 1r11f Jx, -R PV L ::t ~ r, ,~Jf<. 4' .:jf d7 1: iht rrij 1iA~ 
~-l;1t: G-protein ( GTPyS, NaF/AICl 3 ) ,;fa Phospholipase C 
3t~?.t~ ·[3H]-inositol phosphates ~~]A.1.. ; tfiji!i?!!~-H'agji 
3tt jiflJ (PE P ;f\:1 A II) %p 1r 1R. [3 H] -in 0 sit 0 1 ph 0 s p hat e s a~ * 
Ft 1ti c ~* 1!;- YA J:. J'fi ~Jl~ : i! ~ ;l:r. ~-t ::Itt ur tit. *-- -R receptor-G­
. l-d:c A r-e ,tX ...!- 1'1~ 13-;­proteln ~a 0 ~'K.:.:t- /<>J ~ 0 
r, ]Jf<. & ffJ 4ia ;f ~~ *-- ffJ j~JR. " ~t ~Jf<. ' J.£ ~t ~&;f\:1 in 0 sit 0 1 
ph 0 sphat e s a0 ffi.. J.i!- J:. ;l:~ ;}f rJf ;A jJ~ , ~'fi J"/I] Jfu. 1f 1ti &. J.i!- I~i. ur tis *-- ­
~.2 ~ ~ ff. rft 1[1. a0 (Benoit and Granger, 1986; Groszmann, 
1994) 0 
i?!! e.. ;}f :f~. %;ti% B:i tt ,it 0J Jfu. t:i iJ1f 5R 4ia 11 ' ez. # g 1 u c ago n 
( Pizcueta et al., 1990; Mesh et aI., 1991) 'pro stacyclin 
(Sitzmann et aL,1989; Oberti et al., 1993);fa -f\.,1t: 
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(NO) (Lee et aI., 1992; Sieber and Groszmann, 1992) e... 
~~~~k*~~~4~~~.~~k~ffl~~o~~_%~ 
ili ' r'~&~H-6gA~f/74h*..n1z.1f (Huang et al., 1995a; Cahill 
et al., 1995; Niederberger et a1., ]995;) ~k+~Ji (Laffi et 
al., 1993) t*J cAMP ~ cGMP 6g1;- :B$no 0 ..n1z.:-t~~'k~:J ~ 
ft:.m.~ cAMP iX. cGMP pf,:;1~ ~ -=-i;ft..,~·1*:i~;)j'%-1~ (Vane et al., 
1 9 9 0) 0 3t Jl cAMP iX. c G M P 1;- Og :J:W no or ~s 1r ,ti 1]8 it ~t 11[IJ 
iJ 11i- og - l]:.\:' ~~ , eAt- : ~t i~ ~~ (It 0 h eta1.. 19 8 5) ,f,m Be. 
~~i)~fi-rog:B$no (Cornwell and Lincoln. 1989) ':to inositol 
ph 0 S Phat e Og ~ 4 (Rapop 0 rt , 19 8 6; A h net a1., 19 9 2) o-t­
fJ ~& tf;1 £ f/7 4h k:-t. ,k ,[.14h jt ~ cAMP iX. cGMP 6g Jw no or ~s 
~ k ,kg-. Og ~t k.-1fi;&. in 0 sit 0 1 p 11 0 s p ha tei:. ~~ ,1;\ 1Jt.. ~ ~~ 0 
!iift 1.& - ltl::. * 1~ 11t 3t -t- 1t m GTPyS iX. NaF/AlCl 1 -*1] i.~r 
inositol phosphate ~f![E.f' ~r~ft:.m-t-i;f..1!,r±~ogilL~;f(, fi'lJ;J\ 
1r'j k m ;# 1L 1t £1g ill ~~ 0 GTPyS -t-;,t 1t (3Jp or $1[.1 ) :to or ~;f. itt 
't.i Og::E/7 ~&;l:Sj or ~m. inositol phosphate Og ~l~ , {8 -t- or );f.lt.i 'f
*3ij: 7J (EC 5 0 , 111M) J;t,;,t:It ill ~ 'f ~ M- ** T 1~ 1+ ftc 
;J\1r'j GTPyS Og?'Jt-*mi l] 100 /J.M (Jones et aI., 1988) 
ilD NaF/A1C1 3 ;J\1r'j~ organ bath 'f or ~ il] ~tk~ ~fi,i 0 # ~:¥fl 
%~ ili JilA~ Y,A ph 0 S P h 0 lipas e C ht J.f 7t :It 6g ~ ::E/7 mR k 1f.f~ , 
or ~ il] ~t k~ ~ 4 (B 0 v a etaI., 1 9 9 2) ,~t ilD ;J\ 1r'] :t ~~ 1R If] 
G T P y S ' N a F IAl C 13 ~ P 0 s p h 0 lipas e C ;6{'-;,t:It £1g ill ~;f( 'f ' ft:. 




J)l itt ' Sitzmann !!If A (Sitzmann et aL, 1995) .t~ tl:l4. r~ 
~IR ~J ~ ag ;t T rf ' *r, fJ{fi-1"kJ Angiotensin II 1: ft ag Ii 0 Ff 1/f-,. T 
60%, ~ tiT ~~ 1ft Angiotensin II rJt it lx. ag ~t t.~;tO [3H]­
i 11 0 sit 0 1 ph 0 s p hate R J@, 6g F:f- 1/f-,. 1ti T %P 1;)- ag f¥Pf* 0 Pf~ rtTi ' 4. 1: 
"Jt i'- -t ~ rf ' E... ~1t llj] T Jfu.1f rf ex l-adren 0 ceptors ag it 0 ;fO 
jJt.;fo fJ Jt ~ i!t ( Liao et al., 1994) 0 jt..n. Jfu.1f 1/f-,. R ~ ,t1:. jt 
::f 1: Nt j{~if-1i7f - ft ~ - ag ft;'It j!flj (agonist) ,..n. r' ~IR £ ag Jfu. 
if 1/f-,. R ~ 1[1:. k 4. j~ 1: H ift (post-receptor) it fiX. -t~ ,j{\. 
1985 if- E...·1lt* tl:l (Murray and Paller, 1985) 0 
1i7f it G-protein it;:iX. phospholipase C ,1; 1t. ;fo ~'l ~t± 
i 11 0 sit 01 ph 0 s p hat e 6g a !±. §l ~~ jt ~ ,'t Jt ' ::f i¥L :1f ,liJf it -tij tl:l tiT 
~L~ Gq (Milligan, 1995) 4. GTPyS A N aF/Al Cl 3 it;:iX.0 
. -..r il - !-..t.. GTP "),1 -I ­nO ,G -proteJl1 111 'IG ..£ J£ /0" t:l'] ex u-:'" JfL 7C. ( ex\,:tJ 
subunit) (Coleman et al., 1994) 4. it 1r~ 6g 1f J~k J,g *- {?~ -,F0 
.it i¥L GTPy SANaF /Al C1 3 ~11 ~t± rJt a !±. 6g [3 H] -in 0 si tol 
phosphate 4. PVL ::;;t ~ Jt -*. i!t ~ j] - -}j iliJ Cahill !!If A0 
( Cahill et aI., 1994 ) .t~ tb 4. PVL Jt T rf ' G 
protein/adenylyl cyclase/cAMP #. *JGk!k./f 6g 0 rb Jl:t tiT -i'ii ~J!IJ 4. 
r1 RIR ~J f!!:: rf ::f M G -pro t e i n :r.}) jj~:to 't 1r~ Jt i'-iit rJt it;:iX. 6g 1]:3 ~ k 
:1f rJt i!t ~ 6g 0 
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.J:C 9~ , ~ 1f1 CJ flJ ~t ~~ Ht ~ £ Jtj] Q1 ~ f\. ' * r, JW. 61 £ ~t. 
:t..~t ~~ Q(; ~ ~ '*- -;F ,~t ~~ {~ it .l$lt r, IDR Q(; ~EJ¥ (1vlalmqvist 
and Arner, 1988) 0 
~ ..:=.. ~fi 	 P V L :&. Sham ::t iff\. 1t Pro p r an 0 10 1 :&. 
Synephrine i:lZ.J.% 
tb ~~ -z -ntr ~ it mt :£ W j£ 1t ~;; *1 .&. * tf M~_ 1t. IX. 157- -Z 
Synephrine fp: il& - ~~ 3t (Huang et aI., ] 995b) ,~ ,~~S 
iii - j7 J* it Synephrine 1t r~ J3JR ~ & ~ ~ Cardiac Index -Z R 
J.l& ' .J:c it ,~Jt y~ Proprano 10 I 't +'F contro 1 0 
~ Cardiac Index 7J di] , ~ 1" Propranolol -Z{~ , ~ PVL 
4f ~ 1t {](; J}t ~ , CJ -9;0 Propranolol '* 4f ~ if-. r~ .~IR ~!f:: ffJ 40 /\.; ~WJ 
ili ~~~m~o~~ mh7Jdi]'t~~~ *'R~~ 
i!~Jl}] ~1t. ' .t!Ji:.J.:fii Propranolol itlliJ f3rblock {](;11 ffl ' iiT] 
,1; 1t. a-receptor iiT] 1~ Jfrr..if ~t ii5 'raJ FJl h J@. if J:.. #- 1" 1ft 18 
~~ 1f1 {](] ,~t *- t ' I~ it ~ll }] R i!ij T ft it or ~t Jt lliJ ~ ~ 1r11~ ffl0 
{](; 1lf~ i 1.5 	mg/kg/min ~t;- ~ 8 min t:k. i!ij 1tJfrr..!f:: ~1~ t ~ (lliJ 
T.P.R. = lvi.A.P./C.I.) i!ij4f .J:cifJ}t~;l!£ 0 ~ Gilles A~@-
~ f\. propranolol {](; 1lfIJ R 4f 0.33 mg/kg/min ~ ~ 15 min 





*{:£ ;:r:, ;t;S- ~ h;J JS; ;ff sA ~~ i- -Jt 0 Pit ~ T. P . R . .-tf- Sham jJl J~ ~ ?t 
~ , PVL jJl;:;;ff J.±. ~ ~!N 0.4 mg/kg/min at ~;ff sf) ~~ i- -Jt 
$C M; =* 4- J~ ffJ ~JR If:;fv %J :i! fiJ.. j; i- -Jt 1t p, ~JR l~ If: ~ tJ\. ~;ff i0 





" 4 F9 mR. £::t +t- AAJ ..£ tfJ mR. dJ PDBu 7tr 1[: protein 
kinase C fJf A!?J~ ~t ~;fv dJ ACh Ai:. endothium­
dependent if5'lt ~,;fv1ri+fTcr iaijt k 1;4;0:.4 f9 
nJR £::t g\. AAJ tfJ ~JR cf;fv protein kin as e C ;tr nw e~ ~t 
~~&k ~~~~;tr~~#5'lt~~jt ~ffio 
" FJ nJR ~ £ ~\. -* F9 n& & AAJ tfJ nJR k if :r)] ~G fJ~ ;J~ or R 
a.k:4 Phosphoinositide fJ~ iTl ,~, $ tic J:. 0 
ph 0 s p hat e s R J.@., iii ~~ or ~G -Jt rec eptor- G-protein 
coupling fJ~ tiS ~ !B J;t Fo9 0 
T!!J " Synephril1e ~;. ::t If\. or -1+ Iv1. A . P ., T. P . R ., 1Q 
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~I
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Phenylephrine concentration (log M) 
Fig. 1. 	 Contractile responses to phenylephrine in aortic rings 
from PVL (n=12) and Sham (n=12) rats. 
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Fig. 2. 	 Relaxing responses to acetylcholine fronl PVL 
(n=12) and Sham (n=12) aortic rings precontracted 
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Fig. 3. 	PDBu (3 X 10-6 M) induced contractile force 
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Fig. 4. 	 Phenylephrine (10-9-10-3M) induced [3H]-inositol 
phosphates formation in the aorta. (0/0 basal levels) 
* P 0.05 vs. Shaln. Shan1, n=9; PVL, n=9. 
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Fig. 5. 	 Phenylephrine (10-6-1 0-4M) induced eH]-inositol 
phosphates formation in the portal vein. (0/0 basal levels ) 
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Fig. 6. 	 Angiotensin II (10-7-10-5M) induced eH]-inositol 
phosphates formation in the portal vein. (010 basal levels) 
* P 0.05 vs. Sham. Sham, n=7; PVL, n=7. 
55 

Table 1. General data of portal hypertensive (PVL) and sham-operated 
(Sham) rats. 
PVL Sham 
Body weight (g) 367 14 345 := 19 
Portal venous pressure (mmHg) 18.7 _ 0.9* 6.8 -~ 0.3 
AOlta tissue weight (mgl4 mm segment) 3.8 0.1 3.8 =O. J 
POltal vein tissue weight 1.7_0.1* 1.1 0.1 
(mg/4 mm segment) 
Data are eA'jJressed as mean - S.E.M. (n= 8) * P < 0.05 vs. Sham. 
PVL pOltal hypeltensive group: Sham. sham-operated group. 
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Table 2. eH]Inositol phosphates formation stimulated by nonreceptor­
mediated drug. 
PVL Sham 
NaP (10 mM)!A1Ch(90 11M) 182 22% 168 18% 
GTPyS (10-4 M ) 136 -- 10% 136 
Phospholipase C (0.5 U) 144 = 9% 154 = 16%) 
eH]Inositol phosphates fonnation was calculated as percentage of cpm in the presence 

of drug divided by the cpm without drug (basal levels). 

Data are expressed as mean S.E.M. (n := 7 assays for each stimulus). 
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EFFECTCONTRACTION 
Hamet P and 	Tremblay J, 1990 J 
Abbreviations: 	AC, adenyl cyclase; ANF, atrial natriuretic factor; ER. 
endoplasmic reticulum; Os & OJ, stimulatory and 
inhibitory O-proteins for adenyl cyclase,respectively; poe 
& sOC, particulate and soluble guanylate cyclase, 
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Abbreviations: 	R, receptor; PLC, phospholipase C; G, G-protein; PIP2, 
phosphatidylinositol 4,5-bisphosphate; IP3, 1 5­
trisphosphate; DAG, diacylgJycerol; SR, sarcoplasmic 
(endoplasmic) reticulum; PKc, protein kinase C. 
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CHA.l"TGES IN VENOUS PHOSPHOINOSITIDE 
.\;fETABOUSM IN PORTAL HYPERTENSIVE RATS 
y .. T, Huang, S.-P. Chang* and H.·c' Lin. Institute of Traditional 
:V1edicine, School of Medicine. National Yang-tvting university, 
and Department of Medicine. Veterans General Hospital, Taipei, 
Talwan. 
Vascular hyporesponsiveness lS we II documented in portal 
hypertension. However. little is explored in the possible changes 
of pnosphoinositide metaboiism ~n a venous tissue. The present 
study was to investigate the venous inositol phosphate responses in 
portal hypertensive rats. Portal hypertension was induced in 
Sprague-Dawley rats by partial portal vein ligation (PVL). Sham­
operated rats served as controls. Portal veins from each group were 
loaded with [3Hl-myoinositol for 3 [lOurs and phenylephrine (10-6 
- 10-4M), angiotensin II (10-7 - 10-5M), GTP is (l0-4M), NaF 
(10 mM)!AICI3 (90 /.L M), or phospholipase C (0.5 U) was 
incubated fur :0 min. [3HJ-inositol phosphates were extracted 
with CHCI3!CH30HJHCl and sonication and collected after 
Dowex resin dution. 
Two weeks after surgery, portal venous pressure was 
significantly higher, while mean arterial pressure was lower in 
PVL rats after ligation. Phenylephrine- and angiotensin II-induced 
inositol phosphate production was significantly lower in PVL rats 
than in sham rats. Whereas, the inositol phosphate responses to 
GTP I S, NaF /AIC13, or phospholipase C were similar between 
the two groups. This study showed that the receptor-coupled 
inositol phosphate responses were attenuated in the portal vein 
from PYL rats, and the site of impairment was possibly at the 
receptor-G-protein coupling level. 
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